These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7310641)

  • 1. Pharmacokinetics of propranolol.
    Borgström L; Johansson CG; Larsson H; Lenander R
    J Pharmacokinet Biopharm; 1981 Aug; 9(4):419-29. PubMed ID: 7310641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
    Aro A; Anttila M; Korhonen T; Sundquist H
    Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis and disposition of low dose oral propranolol.
    MacKichan JJ; Pyszczynski DR; Jusko WJ
    Res Commun Chem Pathol Pharmacol; 1978 Jun; 20(3):531-8. PubMed ID: 674830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites.
    Walle T; Fagan TC; Walle UK; Oexmann MJ; Conradi EC; Gaffney TE
    Clin Pharmacol Ther; 1981 Dec; 30(6):790-5. PubMed ID: 7307427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and cardiac effects of propranolol in humans.
    Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
    Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical Michaelis-Menten elimination model for propranolol.
    McAinsh J; Gay MA
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):241-5. PubMed ID: 4085525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism by which hydralazine increases propranolol bioavailability.
    Schneck DW; Vary JE
    Clin Pharmacol Ther; 1984 Apr; 35(4):447-53. PubMed ID: 6705442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of propranolol and bendrofluazide formulations.
    McAinsh J; Holmes BF; Baber NS; Young J
    Biopharm Drug Dispos; 1981; 2(2):167-75. PubMed ID: 7248480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.